SG Americas Securities
ALNY icon

SG Americas Securities’s Alnylam Pharmaceuticals ALNY Stock Holding History

SG Americas Securities’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-63,000
Closed -$6K – 3255
2016
Q4 		$6K Buy
+63,000
New +$2.64M ﹤0.01% 3037

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SG Americas Securities's ALNY Position: Q2 2026 in Review

SG Americas Securities reduced its Alnylam Pharmaceuticals (ALNY) stake by 55% in Q2 2026, selling an estimated $9.09M and leaving 24,911 shares worth $7.5M. The position accounts for ﹤0.01% of the portfolio, ranked #942.

SG Americas Securities first reported a position in ALNY in Q3 2013 and has held it in 44 quarters since. The position peaked at $36.2M in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • SG Americas Securities held 24,911 shares of Alnylam Pharmaceuticals worth $7.5M as of Q2 2026.
  • SG Americas Securities sold 30,149 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $9.09M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #942 holding.
  • SG Americas Securities first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 44 quarters since.
  • SG Americas Securities's Alnylam Pharmaceuticals position peaked at $36.2M in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.